GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rakovina Therapeutics Inc (OTCPK:RKVTF) » Definitions » Quick Ratio

RKVTF (Rakovina Therapeutics) Quick Ratio : 1.43 (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Rakovina Therapeutics Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Rakovina Therapeutics's quick ratio for the quarter that ended in Sep. 2024 was 1.43.

Rakovina Therapeutics has a quick ratio of 1.43. It generally indicates good short-term financial strength.

The historical rank and industry rank for Rakovina Therapeutics's Quick Ratio or its related term are showing as below:

RKVTF' s Quick Ratio Range Over the Past 10 Years
Min: 0.72   Med: 6.8   Max: 26.94
Current: 1.43

During the past 3 years, Rakovina Therapeutics's highest Quick Ratio was 26.94. The lowest was 0.72. And the median was 6.80.

RKVTF's Quick Ratio is ranked worse than
72.95% of 1497 companies
in the Biotechnology industry
Industry Median: 3.4 vs RKVTF: 1.43

Rakovina Therapeutics Quick Ratio Historical Data

The historical data trend for Rakovina Therapeutics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rakovina Therapeutics Quick Ratio Chart

Rakovina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Quick Ratio
26.96 9.97 4.07

Rakovina Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.38 4.07 0.72 1.89 1.43

Competitive Comparison of Rakovina Therapeutics's Quick Ratio

For the Biotechnology subindustry, Rakovina Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rakovina Therapeutics's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rakovina Therapeutics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Rakovina Therapeutics's Quick Ratio falls into.


;
;

Rakovina Therapeutics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Rakovina Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.472-0)/0.116
=4.07

Rakovina Therapeutics's Quick Ratio for the quarter that ended in Sep. 2024 is calculated as

Quick Ratio (Q: Sep. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.883-0)/0.619
=1.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rakovina Therapeutics  (OTCPK:RKVTF) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Rakovina Therapeutics Quick Ratio Related Terms

Thank you for viewing the detailed overview of Rakovina Therapeutics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Rakovina Therapeutics Business Description

Traded in Other Exchanges
Address
595 Burrard Street, P.O. Box 49314, Suite 2600, Three Bentall Centre, Vancouver, BC, CAN, V6B 0A5
Rakovina Therapeutics Inc is engaged in drug discovery research, preclinical and clinical development, and regulatory affairs necessary to advance breakthrough innovations to become potential life-changing treatments in the oncology field. Its oncology pipeline has the potential to deliver biomarker-driven treatments for patients across multiple tumor types. Some of its products in the pipeline include kt-2000 AI, kt-3000 series. Rakovina gained exclusive use of the Deep Docking AI Platform, enabling it to significantly speed up identifying potential drugs for DNA damage response.